You are now
leaving this site

If you'd like to stay, click CANCEL.
CONTINUE
CANCEL
X
  • Home
  • >
  • Access & Patient Support
Not an actual patient.

Opening doors to help your patients with APDS move forward

APDS Assist can help you:

Enroll your patients with APDS in our
comprehensive program
Gain information about patient-specific insurance requirements for Joenja
Learn more about our support services,
including our APDS Clinical Educators (ACEs)*
*Please note that ACEs do not offer medical or treatment advice or replace discussions with a physician.

APDS Assist
Care Coordinators

APDS Assist
Care Coordinators

Here to help you navigate coverage, access, and other support options
when you prescribe Joenja.

ACEs

ACEs

Provide one-on-one support and educational resources for you
and your patients.

APDS Assist
Specialty Pharmacists

APDS Assist
Specialty Pharmacists

Available to answer questions you
and your patients may have about
their Joenja medication.

Enrolling your patients

in APDS Assist is quick and simple to do

1
Complete the enrollment form
2
Have your patient fill out and sign the consent form to receive
APDS Assist Support Services
3
Fax the enrollment form, the patient consent form, and any
additional documentation to APDS Assist at 1-833-850-2727
download enrollment form
Connect with a

Care Coordinator at APDS Assist

If you or your office a needs to get in contact with a Care Coordinator,
call 1-866-796-APDS (2737) from 8 AM-8 PM ET, Monday-Friday.

A Care Coordinator can also connect you
to a pharmacist.

Starter Program

Our commitment is to get your patient started on Joenja as quickly as possible while we work with your office to
process any insurance requirements.

Patient support

ACEs* can help your patients connect with local and nationwide support
groups and educational resources
along their Joenja journey.

Helping with coverage

Access to Joenja is a priority of
APDS Assist. Depending on the patient’s insurance and other eligibility criteria,
a Care Coordinator can help
identify financial resources.
*Please note that ACEs do not offer medical or treatment advice or replace discussions with a physician.
Learn about the

APDS Assist team

Watch these informative videos to enhance the conversations you may be having with patients about APDS Assist.

Find out more about how APDS Assist works to support you by watching this short video.

NOW PLAYING

Up Next

Find out more about how APDS Assist works to
support you by watching
this short video.

NOW PLAYING

Up Next

Learn how ACEs get you started with confidence and partner with you throughout your Joenja treatment journey.
Expand

Indications and Usage

JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Important Safety Information

Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA.

Indications and Usage

JOENJA® (leniolisib) is a kinase inhibitor indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older.

Important Safety Information

Verify pregnancy status in females of reproductive potential prior to initiating treatment with JOENJA.

JOENJA may cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus and to use highly effective methods of contraception during treatment with JOENJA and for 1 week after the last dose of JOENJA.

Live, attenuated vaccinations may be less effective if administered during JOENJA treatment.

Use of JOENJA in patients with moderate to severe hepatic impairment is not recommended. There is no recommended dosage for patients weighing less than 45 kg.

The most common adverse reactions (incidence >10%) seen in clinical trials were headache, sinusitis, and atopic dermatitis.

Seven (33%) patients receiving JOENJA developed an absolute neutrophil count (ANC) between 500 and 1500 cells/microL. No patients developed an ANC <500 cells/ microL and there were no reports of infection associated with neutropenia.

Before prescribing JOENJA, please read the full Prescribing Information.

About Joenja

About Joenja

Clinical Data

Clinical Trials Efficacy Safety & Tolerability Additional Safety

Dosing & Administration

Dosing & Administration

Access & Patient Support

APDS Assist

What is APDS?

What is APDS?

Resources

Resources
Prescribing Information Pharming Contact Us Privacy Policy Terms of Use
Sitemap Cookie Policy NavigateAPDS

Joenja and logo are registered trademarks of Pharming Intellectual Property, B.V.

©2024 Pharming Healthcare, Inc. All rights reserved.
JOE-US-2023-0026 v6 10/24

Privacy settings

Decide which cookies you want to allow.

You can change these settings at any time. However, this can result in some functions no longer being available. For information on deleting the cookies, please consult your browser’s help function.

Learn more about the cookies we use.

With the slider, you can enable or disable different types of cookies:

  • Block all
  • Essentials
  • Functionality
  • Analytics
  • Advertising

This website will:

This website won't:

  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Keep track of what you input in a shopping cart
  • Essential: Authenticate that you are logged into your user account
  • Essential: Remember language version you selected
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Advertising: Tailor information and advertising to your interests based on e.g. the content you have visited before. (Currently we do not use targeting or targeting cookies.
  • Advertising: Gather personally identifiable information such as name and location
  • Remember your login details
  • Essential: Remember your cookie permission setting
  • Essential: Allow session cookies
  • Essential: Gather information you input into a contact forms, newsletter and other forms across all pages
  • Essential: Keep track of what you input in a shopping cart
  • Essential: Authenticate that you are logged into your user account
  • Essential: Remember language version you selected
  • Functionality: Remember social media settings
  • Functionality: Remember selected region and country
  • Analytics: Keep track of your visited pages and interaction taken
  • Analytics: Keep track about your location and region based on your IP number
  • Analytics: Keep track of the time spent on each page
  • Analytics: Increase the data quality of the statistics functions
  • Advertising: Tailor information and advertising to your interests based on e.g. the content you have visited before. (Currently we do not use targeting or targeting cookies.
  • Advertising: Gather personally identifiable information such as name and location
Save & Close